Shenzhen S.E.
06:00:00 2024-05-14 pm EDT
5-day change
1st Jan Change
9.29
CNY
-1.90%
-8.20%
-3.53%
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
April 26, 2021 at 12:25 pm EDT
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was CNY 223.082 million compared to CNY 151.034 million a year ago. Operating loss was CNY 2.148 million compared to CNY 54.097 million a year ago. Net income was CNY 1.018 million compared to net loss of CNY 43.650 million a year ago. Basic earnings per share from continuing operations was CNY 0.0045 compared to basic loss per share from continuing operations of CNY 0.2095 a year ago.
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the First Quarter Ended March 31, 2024
Apr. 12
CI
ShanXi C&Y Pharmaceutical Group Co.,LTD. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 18
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
23-10-24
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
23-08-04
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 184.999997 million in funding
23-06-29
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
23-04-24
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022
23-04-24
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
22-10-27
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
22-08-25
CI
Hangzhou Qianyuan Baoling Pharmaceutical Co., Ltd. announced that it expects to receive CNY 105 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
22-06-01
CI
C&Y Pharmaceutical Raises $15.5 Million in Private Placement
22-05-09
MT
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it has received CNY 109.999995 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
22-04-28
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
22-04-28
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
21-10-26
CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
21-08-27
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 130 million in funding from Caitong Fund Management Co., Ltd., Ningbo Ningju Asset Management Center (Limited Partnership), Nuode Asset Management Co., Ltd., and other investors
21-08-26
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. and Chen Jinsong entered into an equity transfer agreement to acquire 15.43% stake in Sichuan C&Y Traditional Chinese Medicine Co., Ltd. from Chen Renhu and Tang Wenjing.
21-05-26
CI
ShanXi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
21-04-26
CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020
21-04-26
CI
Hangzhou Pollen Group Company Limited announced that it has received CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
20-12-22
CI
Shenzhen Purcotton Technology Co. Ltd announced that it expects to receive CNY 80 million in funding from ShanXi C&Y Pharmaceutical Group Co., LTD.
20-11-26
CI
Shenzhen PureH2B Technology Co., Ltd. announced that it expects to receive CNY 100 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
20-11-26
CI
Hangzhou Pollen Group Company Limited announced that it expects to receive CNY 115 million in funding from ShanXi C&Y Pharmaceutical Group Co., Ltd.
20-11-26
CI
Shanxi C&Y Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
20-10-28
CI
ShanXi C&Y Pharmaceutical Group Co., LTD. announced that it has received CNY 139.999998 million in funding
20-10-11
CI
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
ShanXi C&Y Pharmaceutical Group Co., Ltd. is principally engaged in the research, development, manufacture and distribution of pharmaceuticals. The Companyâs main products include anti-infective agents, respiratory system agents, cardiovascular drugs, antidepressant drugs, urinary system agents, pediatric agents and other drugs, as well as pharmaceutical raw materials and pharmaceutical intermediates. It also involves in the manufacture and distribution of health food products, as well as the provision of deoxyribonucleic acid (DNA) genetic preservation and pregnant environment testing services. The Company distributes its products in domestic market.
More about the company
1st Jan change
Capi.
-3.53% 316M +31.37% 588B -2.60% 364B +20.83% 326B +5.69% 285B +14.83% 239B +9.93% 210B -6.95% 200B +10.77% 167B +0.10% 161B
Other Pharmaceuticals
+951% of historical
More than 20 years
Our Experts
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1
SHANXI C&Y PHARMACEUTICAL GROUP CO.,LTD. 